Dr. Wayne Macfadden, a graduate from the State University of New York at Buffalo School of Medicine, serves as the Global Medical Affairs and Sleep Therapeutic Area Lead with Jazz Pharmaceuticals in Philadelphia. Before this, Wayne Macfadden, MD, was a Psychiatrist at Spirit Lake Reservation in Fort Totten, North Dakota, where among other responsibilities, he utilized suboxone to treat opiate use disorders.
The World Health Organization's 2021 report revealed that opioid overdose claimed 115,000 lives in 2017. The surging opioid addiction in the US is а mounting concern, prompting healthcare organizations to address it with specialized treatments like suboxone, a combination of naloxone and buprenorphine. Buprenorphine, а partial opioid agonist (а drug that activates receptors in the brain) in suboxone, mitigates withdrawal symptoms and cravings, while naloxone, an opioid antagonist, safeguards against opioid misuse. Combined, these drugs offer patients relief from withdrawal symptoms and help against relapsing. Suboxone's аbility to block opioid gratification and prevent overdoses makes it an invaluable tool in treating opioid use disorder. When treating patients with opioid use disorder (OUD), abstaining from using opioids for 12 to 24 hours is vital. The patient should also be in the early stages of withdrawal before beginning treatment. Once a patient has reduced their opioid use, suboxone can help them reduce cravings and other effects.
0 Comments
|
AuthorWayne Macfadden MD: Expert in both Clinical and Research Psychiatry. Archives
March 2024
Categories |